NeuroPace Inc. Announces Annual Meeting of Stockholders on June 7, 2024
Ticker: NPCE · Form: DEF 14A · Filed: Apr 22, 2024 · CIK: 1528287
| Field | Detail |
|---|---|
| Company | Neuropace Inc (NPCE) |
| Form Type | DEF 14A |
| Filed Date | Apr 22, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, NeuroPace, Director Election, Auditor Ratification
AI Summary
NeuroPace Inc (NPCE) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. NeuroPace Inc. will hold its Annual Meeting of Stockholders virtually on June 7, 2024, at 10:30 a.m. Pacific time. The meeting agenda includes the election of three Class III directors: Uri Geiger, Rakhi Kumar, and Renee Ryan. Stockholders will vote on ratifying PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024. The record date for stockholders eligible to vote is April 10, 2024. The meeting will be conducted via live webcast at www.virtualshareholdermeeting.com/NPCE2024.
Why It Matters
For investors and stakeholders tracking NeuroPace Inc, this filing contains several important signals. The election of directors and ratification of the auditor are key governance activities that directly impact the company's leadership and financial oversight. The virtual format allows for broader participation from stockholders regardless of location, but requires specific login procedures.
Risk Assessment
Risk Level: low — NeuroPace Inc shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
Analyst Insight
Stockholders should review the director nominees and auditor ratification proposals before the June 7, 2024 meeting.
Key Numbers
- June 7, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
- 10:30 a.m. Pacific time — Meeting Time (Time of the virtual Annual Meeting)
- April 10, 2024 — Record Date (Date to determine stockholders eligible to vote)
- 2027 — Director Term End (Year directors will serve until)
- 2024 — Fiscal Year End (Fiscal year for which auditor is being ratified)
Key Players & Entities
- NeuroPace Inc. (company) — Registrant
- Uri Geiger (person) — Director nominee
- Rakhi Kumar (person) — Director nominee
- Renee Ryan (person) — Director nominee
- PricewaterhouseCoopers LLP (company) — Independent registered public accounting firm
- June 7, 2024 (date) — Annual Meeting date
- April 10, 2024 (date) — Record date for stockholders
- www.virtualshareholdermeeting.com/NPCE2024 (url) — Meeting webcast link
FAQ
When did NeuroPace Inc file this DEF 14A?
NeuroPace Inc filed this Proxy Statement (DEF 14A) with the SEC on April 22, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by NeuroPace Inc (NPCE).
Where can I read the original DEF 14A filing from NeuroPace Inc?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by NeuroPace Inc.
What are the key takeaways from NeuroPace Inc's DEF 14A?
NeuroPace Inc filed this DEF 14A on April 22, 2024. Key takeaways: NeuroPace Inc. will hold its Annual Meeting of Stockholders virtually on June 7, 2024, at 10:30 a.m. Pacific time.. The meeting agenda includes the election of three Class III directors: Uri Geiger, Rakhi Kumar, and Renee Ryan.. Stockholders will vote on ratifying PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024..
Is NeuroPace Inc a risky investment based on this filing?
Based on this DEF 14A, NeuroPace Inc presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
What should investors do after reading NeuroPace Inc's DEF 14A?
Stockholders should review the director nominees and auditor ratification proposals before the June 7, 2024 meeting. The overall sentiment from this filing is neutral.
How does NeuroPace Inc compare to its industry peers?
NeuroPace Inc. operates in the medical device sector, specifically focusing on neurostimulation for epilepsy.
Are there regulatory concerns for NeuroPace Inc?
The filing is a standard DEF 14A (Definitive Proxy Statement) under the Securities Exchange Act of 1934, used for soliciting shareholder votes.
Industry Context
NeuroPace Inc. operates in the medical device sector, specifically focusing on neurostimulation for epilepsy.
Regulatory Implications
The filing is a standard DEF 14A (Definitive Proxy Statement) under the Securities Exchange Act of 1934, used for soliciting shareholder votes.
What Investors Should Do
- Review the biographies and qualifications of the director nominees (Uri Geiger, Rakhi Kumar, Renee Ryan).
- Evaluate the proposal to ratify PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024.
- Ensure you have your 16-digit control number to access the virtual meeting and vote.
Key Dates
- 2024-06-07: Annual Meeting of Stockholders — Election of directors and ratification of auditors
- 2024-04-10: Record Date — Determines eligibility to vote at the Annual Meeting
Year-Over-Year Comparison
This filing is a DEF 14A, indicating it's the definitive proxy statement for the upcoming annual meeting, following any preliminary filings.
Filing Stats: 4,772 words · 19 min read · ~16 pages · Grade level 11.4 · Accepted 2024-04-22 17:00:53
Filing Documents
- ny20023787x1_def14a.htm (DEF 14A) — 592KB
- ny20023787x1_pc01.jpg (GRAPHIC) — 644KB
- ny20023787x1_pc02.jpg (GRAPHIC) — 549KB
- 0001140361-24-021062.txt ( ) — 2236KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT ​ ​ 17 INFORMATION REGARDING EXECUTIVE OFFICERS ​ ​ 19
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 20 DIRECTOR COMPENSATION ​ ​ 27 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS ​ ​ 29 TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION ​ ​ 30 OTHER INFORMATION FOR STOCKHOLDERS ​ ​ 31 OTHER MATTERS ​ ​ 32 i TABLE OF CONTENTS QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the “ SEC ”), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the “ Notice ”) because the Board of Directors of NeuroPace, Inc. (sometimes referred to as the “ Company ” or “ NeuroPace ”) is soliciting your proxy to vote at the Annual Meeting of Stockholders, including at any adjournments or postponements of the meeting (the “ Annual Meeting ”). All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about April 22, 2024 to all stockholders of record entitled to vote at the Annual Meeting. Will I receive any other proxy materials by mail? You will not receive any additional proxy materials via mail unless you request a printed copy in accordance with the instructions set forth in the Notice. We may elect to send you a proxy card, along with a second Notice, after 10 calendar days have passed since our first mailing of the Notice. How do I attend the Annual Meeting? This year’s Annual Meeting will be a vir